Order Article Reprints

Zehentmayr F, Feurstein P, Ruznic E, Langer B, Grambozov B, Klebermass M, Hochreiter A, Purevdorj A, Gruber G, Minasch D, et al. Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR). Cancers. 2025; 17(9):1443. https://doi.org/10.3390/cancers17091443

Zehentmayr, Franz, Petra Feurstein, Elvis Ruznic, Brigitte Langer, Brane Grambozov, Marisa Klebermass, Alexandra Hochreiter, Ayurzana Purevdorj, Georg Gruber, Danijela Minasch, and et al. 2025. "Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)" Cancers 17, no. 9: 1443. https://doi.org/10.3390/cancers17091443

Zehentmayr, F., Feurstein, P., Ruznic, E., Langer, B., Grambozov, B., Klebermass, M., Hochreiter, A., Purevdorj, A., Gruber, G., Minasch, D., Breitfelder, B., Steffal, C., Kirchhammer, K., Stranzl, H., Röder, F., & Dieckmann, K., on behalf of the ALLSTAR Group. (2025). Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR). Cancers, 17(9), 1443. https://doi.org/10.3390/cancers17091443